Author Archives: Sandra Klausing

Overcoming Challenges in Viral Vector Production for Gene Therapy Using HEK Cell Cultures

An estimated 300 million people worldwide live with rare diseases, and over 70% of such disorders are caused by genetic mutations (1, 2). Cell and gene therapies offer hope and potential cures for many previously untreatable diseases. Accordingly, the global gene therapy market is expected to be worth USD 5.02 billion by 2028, a significant growth from USD 1.46 billion in 2020 (3). Manufacturing gene therapies will be a key challenge over the next two decades. But just a few…